A Serum Multi-Parametric Analysis Identifies an Early Innate Immune Signature Associated to Increased Vaccine-Specific Antibody Production and Seroconversion in Simultaneous COVID-19 mRNA and Cell-Based Quadrivalent Influenza Vaccination.

Autor: Severa M; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Ricci D; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Etna MP; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Facchini M; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Puzelli S; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Fedele G; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Iorio E; High Resolution NMR Unit, Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy., Cairo G; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Castrechini S; ASL ROMA 1, Regione Lazio, 00145 Rome, Italy., Ungari V; ASL ROMA 1, Regione Lazio, 00145 Rome, Italy., Iannetta M; Infectious Disease Clinic, Tor Vergata University Hospital, 00133 Rome, Italy., Leone P; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Chirico M; High Resolution NMR Unit, Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy., Pisanu ME; High Resolution NMR Unit, Core Facilities, Istituto Superiore di Sanità, 00161 Rome, Italy., Bottazzi B; Department of Inflammation and Immunology, Humanitas Clinical and Research Centre-IRCCS, 20019 Milan, Italy., Benedetti L; Infectious Disease Clinic, Tor Vergata University Hospital, 00133 Rome, Italy., Sali M; Department of Laboratory and Infectious Sciences, Fondazione Policlinico Universitario A. Gemelli IRCCS, 00168 Rome, Italy.; Department of Basic Biotechnological Sciences, Intensive and Perioperative Clinics, Università Cattolica del Sacro Cuore, 00168 Rome, Italy., Bartolomucci R; ASL ROMA 1, Regione Lazio, 00145 Rome, Italy., Balducci S; Metabolic Fitness Association, Monterotondo, 00015 Rome, Italy., Garlanda C; Department of Inflammation and Immunology, Humanitas Clinical and Research Centre-IRCCS, 20019 Milan, Italy.; Department of Biomedical Sciences, Humanitas University, 20090 Milan, Italy., Stefanelli P; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Spadea A; ASL ROMA 1, Regione Lazio, 00145 Rome, Italy., Palamara AT; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy., Coccia EM; Department of Infectious Diseases, Istituto Superiore di Sanità, 00161 Rome, Italy.
Jazyk: angličtina
Zdroj: Vaccines [Vaccines (Basel)] 2024 Sep 13; Vol. 12 (9). Date of Electronic Publication: 2024 Sep 13.
DOI: 10.3390/vaccines12091050
Abstrakt: In this pilot study, a multi-parametric analysis comparing immune responses in sera of adult healthy subjects (HS) or people with type 2 diabetes mellitus (T2D) undergoing the single or simultaneous administration of mRNA-based COVID-19 and cellular quadrivalent inactivated influenza vaccines was conducted. While SARS-CoV-2 antibodies remains comparable, influenza antibody titers and seroconversion were significantly higher upon simultaneous vaccination. Magnitude of anti-influenza humoral response closely correlated with an early innate immune signature, previously described for the COVID-19 vaccine, composed of IL-15, IL-6, TNF-α, IFN-γ, CXCL-10 and here extended also to acute-phase protein Pentraxin 3. People with T2D receiving simultaneous vaccination showed a protective response comparable to HS correlating with the early induction of IFN-γ/CXCL10 and a significant reduction of the circulating glucose level due to increased oxidation of glucose digestion and consumption. These data, although preliminary and in-need of validation in larger cohorts, might be exploited to optimize future vaccination in people with chronic disorders, including diabetes.
Databáze: MEDLINE
Externí odkaz: